Kaoxiang Sun,Rongcai Liang,Qilin Wang,Wenyan Wang,Wanhui Liu,Youxin Li
申请号：
US16525502
公开号：
US20190343840A1
申请日:
2019.07.29
申请国别(地区):
US
年份:
2019
代理人:
摘要：
A risperidone sustained release microsphere formulation is provided. The microsphere formulation comprise risperidone or 9-hydroxy risperidone or salts thereof, and a polymer blend having a first uncapped lactide-glycolide copolymer and a second uncapped lactide-glycolide copolymer, in which the first uncapped lactide-glycolide copolymer is a copolymer with a high intrinsic viscosity and the second uncapped lactide-glycolide copolymer is a copolymer with a low intrinsic viscosity. The sustained release microsphere formulation according to an embodiment of the present disclosure is suitable for large-scale industrialized production with improved stability, the in vivo release behavior of which will not change after long-term storage.
